09.02.2011

Intervet/Schering Plough Animal Health has reported full-year 2010 revenues of $2.97 billion, up 8% on the $2.72bn from 2009 trading.
The year was the first full 12 months under Merck’s ownership, after the latter completed its acquisition of Schering-Plough in mid-Q4 2009.

Merck had earlier divested its half share of the Merial animal health business to its joint equity partner sanofi-aventis for $3.16bn. Merck and sanofi are intending to merge the two animal health businesses into the industry-leading Merial-Intervet joint venture, subject to regulatory approval. This deal, originally scheduled to complete in Q1 this year is now likely to take place in Q2, says the Merck financial statement.

Intervet/SPAH made full year 2010 sales of $2.94bn, up from $2.72bn in 2009 and close to the $2.97bn in 2008 (AnimalPharm).